ProCE Banner Activity

Slides on Timely Treatment for COVID-19

Slideset Download
Expert review of the rationale, clinical data, and treatment recommendations supporting timeliness in the administration of therapies that act directly against SARS-CoV-2.

Released: May 11, 2022

Expiration: May 10, 2023

Share

Faculty

Michael G. Ison

Michael G. Ison, MD, MS

Professor
Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Arthur Kim

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Lynora Saxinger

Lynora Saxinger, MD, FRCPC, CTropMed

Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta, Canada

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Michael G. Ison, MD, MS

Professor
Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he has served on the scientific advisory board for Kintor Pharmaceuticals and as an NIH-funded site investigator for a prevention trial for casirivimab/imdevimab.

Lynora Saxinger, MD, FRCPC, CTropMed

Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta, Canada

Lynora Saxinger, MD, FRCPC, CTropMed, has no relevant conflicts of interest to report.